Patents by Inventor Robert J. Bayer

Robert J. Bayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170136104
    Abstract: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Application
    Filed: January 19, 2017
    Publication date: May 18, 2017
    Inventors: Shawn Defrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Panneerselvam
  • Publication number: 20170007712
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Application
    Filed: August 1, 2016
    Publication date: January 12, 2017
    Applicant: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David Hakes, Caryn L. Bowe, Xi Chen
  • Publication number: 20160361427
    Abstract: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 15, 2016
    Inventors: Shawn Defrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Panneerselvam
  • Publication number: 20160200795
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Application
    Filed: December 18, 2015
    Publication date: July 14, 2016
    Applicant: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, Caryn Bowe, David James Hakes, Xi Chen
  • Publication number: 20160193353
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Application
    Filed: March 16, 2016
    Publication date: July 7, 2016
    Applicant: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, Caryn Bowe, David James Hakes, Xi Chen
  • Publication number: 20160184412
    Abstract: Conjugates between Factor IX and PEG moieties, are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Application
    Filed: January 25, 2016
    Publication date: June 30, 2016
    Inventors: Shawn Defrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Panneerselvam
  • Publication number: 20150343080
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Application
    Filed: May 26, 2015
    Publication date: December 3, 2015
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn L. Bowe, Xi Chen
  • Publication number: 20150125437
    Abstract: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 7, 2015
    Inventors: Shawn Defrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Panneerselvam
  • Patent number: 8911967
    Abstract: The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: December 16, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Susann Taudte, Walter Scott Willett, Robert J. Bayer, Matthew Kalo
  • Patent number: 8853161
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: October 7, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn Bowe, Xi Chen
  • Publication number: 20140294762
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 2, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn L. Bowe, Xi Chen
  • Patent number: 8791070
    Abstract: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: July 29, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Paneerselvam
  • Publication number: 20140170728
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Application
    Filed: December 6, 2013
    Publication date: June 19, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, Caryn Bowe, David James Hakes, Xi Chen
  • Publication number: 20140154230
    Abstract: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Application
    Filed: October 17, 2013
    Publication date: June 5, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Robert J. Bayer, Caryn Bowe, Panneerselvam Krishnasamy
  • Patent number: 8716240
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: May 6, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, Caryn Bowe, David James Hakes, Xi Chen
  • Patent number: 8716239
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: May 6, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, Caryn Bowe, David James Hakes, Xi Chen
  • Publication number: 20140112903
    Abstract: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Application
    Filed: October 11, 2013
    Publication date: April 24, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Shawn DeFrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Paneerselvam
  • Patent number: 8633157
    Abstract: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: January 21, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Robert J. Bayer, David A. Zopf
  • Patent number: 8632770
    Abstract: The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: January 21, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Robert J. Bayer, Caryn Bowe, Krishnasamy Panneer-Selvam
  • Patent number: 8404809
    Abstract: Conjugates between Factor IX and PEG moieties are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: March 26, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Robert J. Bayer, Caryn L. Bowe, Krishnasamy Panneerselvam